Q linea AB Total Liabilities

Latest as of March 2026: Skr29.06 Million SEK ≈ $3.13 Million USD

Q linea AB total liabilities. Based on the latest financial reports, Q linea AB (QLINEA) has total liabilities worth Skr29.06 Million SEK (≈ $3.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check QLINEA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Q linea AB (2015–2025)

Total liabilities of Q linea AB from 2015 to 2025. This chart illustrates how Q linea AB's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Q linea AB's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Q linea AB Competitors by Total Liabilities

The table below lists competitors of Q linea AB ranked by their total liabilities.

Company Country Total Liabilities
Modi Rubber Limited
NSE:MODIRUBBER
India Rs-6.77 Billion
Nova Wellness Group Bhd
KLSE:0201
Malaysia RM8.89 Million
Trajectory Alpha Acquisition Corp
NYSE:TCOA
USA $9.81 Million
Vitreous Glass Inc
V:VCI
Canada CA$1.50 Million
AfroCentric Investment Corp
JSE:ACT
South Africa ZAC2.12 Billion
Shinfox Energy Co Ltd
TW:6806
Taiwan NT$43.23 Billion
Aaron Industries Limited
NSE:AARON
India Rs-486.12 Million
Zenith Minerals Ltd
AU:ZNC
Australia AU$974.40K

Liability Composition Analysis (2015–2025)

This chart breaks down Q linea AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Q linea AB's balance sheet.

Liquidity & Leverage Metrics

Q linea AB Total Liabilities Ratios Explained

Q linea AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 10.48 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Q linea AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Q linea AB (2015–2025)

The table below shows the annual total liabilities of Q linea AB from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 Skr31.66 Million
≈ $3.41 Million
-81.95%
2024-12-31 Skr175.45 Million
≈ $18.88 Million
+314.37%
2023-12-31 Skr42.34 Million
≈ $4.56 Million
-7.47%
2022-12-31 Skr45.76 Million
≈ $4.92 Million
+27.65%
2021-12-31 Skr35.84 Million
≈ $3.86 Million
+11.89%
2020-12-31 Skr32.03 Million
≈ $3.45 Million
-4.26%
2019-12-31 Skr33.46 Million
≈ $3.60 Million
+30.66%
2018-12-31 Skr25.61 Million
≈ $2.76 Million
+51.67%
2017-12-31 Skr16.89 Million
≈ $1.82 Million
+100.84%
2016-12-31 Skr8.41 Million
≈ $904.73K
+51.37%
2015-12-31 Skr5.55 Million
≈ $597.70K
--

About Q linea AB

ST:QLINEA Sweden Medical Devices
Market Cap
$30.38 Million
Skr282.34 Million SEK
Market Cap Rank
#23538 Global
#444 in Sweden
Share Price
Skr14.90
Change (1 day)
+2.41%
52-Week Range
Skr14.55 - Skr33.15
All Time High
Skr176.50
About

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more